Study of direct costs of type 1 diabetes mellitus in Andalusian patients aged 2–16 years

Casaño, María Álvarez; Montejo, María del Mar Alonso; Leiva-Gea, Isabel; Hinojosa, J.; Mata, M; Macías, Francisco; Pérez, María del Mar Romero; Toro, Marta de; Martínez, Gabriela; Munguira, Pilar; Vivas, Gustavo; Siguero, Juan Pedro López

doi:10.1016/j.endien.2019.03.007

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless, technologic advances and increased usage of CGM in recent years can also be a reason for the increased cost estimate [28]. In several cost analyses in children, technology use was an important contributor to costs [9,10,12,13,15,16]. In line with these studies, we observed a significant increase in costs when stratified by treatment regimen.…”

Section: Discussionsupporting

confidence: 81%

“…Beneficial effects on outcomes may well balance out these additional costs in the long run, but insight in healthcare utilization and costs is greatly warranted to equally and efficiently distribute available resources. The few studies that investigated healthcare use and costs in pediatric diabetes care were not on a national level or not recently performed, thus not reflecting current pediatric diabetes practices [10][11][12][13][14][15][16][17][18][19]. Previously reported factors to influence costs were medication, hospitalisations, and the use of technology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Healthcare expenditure and technology use in pediatric diabetes care

et al. 2023

View full text Add to dashboard Cite

Background Diabetes mellitus is one of the most common chronic diseases in childhood. With more advanced care options including ever-evolving technology, allocation of resources becomes increasingly important to guarantee equal care for all. Therefore, we investigated healthcare resource utilization, hospital costs, and its determinants in Dutch children with diabetes. Methods We conducted a retrospective, observational analysis with hospital claims data of 5,474 children with diabetes mellitus treated in 64 hospitals across the Netherlands between 2019–2020. Results Total hospital costs were €33,002,652 per year, and most of these costs were diabetes-associated (€28,151,381; 85.3%). Mean annual diabetes costs were €5,143 per child, and treatment-related costs determined 61.8%. Diabetes technology significantly increased yearly diabetes costs compared to no technology: insulin pumps € 4,759 (28.7% of children), Real-Time Continuous Glucose Monitoring € 7,259 (2.1% of children), and the combination of these treatment modalities € 9,579 (27.3% of children). Technology use increased treatment costs significantly (5.9 – 15.3 times), but lower all-cause hospitalisation rates were observed. In all age groups, diabetes technology use influenced healthcare consumption, yet in adolescence usage decreased and consumption patterns changed. Conclusions These findings suggest that contemporary hospital costs of children with diabetes of all ages are driven primarily by the treatment of diabetes, with technology use as an important additive factor. The expected rise in technology use in the near future underlines the importance of insight into resource use and cost-effectiveness studies to evaluate if improved outcomes balance out these short-term costs of modern technology.

show abstract